Promising – News Journos

Flying Car Promising 620-Mile Range Set for Launch

News Editor — Tue, 03 Jun 2025 10:17:42 +0000

This article is published by News Journos

The dream of flying cars is inching closer to reality as the Klein Vision AirCar is set for imminent certification. Designed by Slovakian inventor Štefan Klein, this innovative vehicle promises to transform travel by seamlessly transitioning from driving to flying in just over a minute. With over 30 years of development and extensive testing behind it, the AirCar aims to revolutionize how we navigate traffic and travel distances.

Article Subheadings
1) A dream decades in the making
2) From the road to the sky in minutes
3) Performance that impresses
4) What licenses do you need to operate the AirCar?
5) Pricing and who the AirCar is for

A dream decades in the making

The AirCar’s journey began in Slovakia, where Štefan Klein and his engineering team embarked on a mission to make flying cars a viable option since the late 1980s. This unique vehicle has undergone rigorous development over the past decades, including the completion of over 500 test flights. The culmination of this decades-long effort is finally coming to fruition as the AirCar gears up for official certification aimed later this year. Customer deliveries are eagerly anticipated in early 2026, possibly marking the dawn of a new era in transportation. Additionally, there are plans for an amphibious version that is designed to land on water, expanding its potential applications.

From the road to the sky in minutes

One of the AirCar’s most impressive features is its ability to transition from a road-worthy vehicle to an aircraft in about 80 seconds. On the ground, it resembles a luxurious sports coupe with four wheels, effortlessly blending in with traditional automobiles. When it’s time to take to the skies, drivers can simply drive to a runway, press a button, and watch as the wings unfold and the tail extends. No manual adjustments are necessary, making the transformation efficient and user-friendly. During this process, the steering wheel morphs into a flight yoke, and additional pedals emerge for rudder control, ensuring a smooth transition into flying mode. This intuitive design allows individuals with private pilot licenses to operate the AirCar without needing extensive retraining.

Performance that impresses

Under its sleek exterior, the AirCar is powered by a range of three 3.2-liter V6 engines sourced from South African company Adept Airmotive. These engine options range from a base model producing 280 horsepower to a high-performance variant that delivers 340 horsepower with twin turbochargers. On the road, the AirCar can reach speeds of approximately 124 mph, with driving dynamics reminiscent of a sports car. In the air, it can cruise at speeds of around 155 mph and boasts a remarkable range of up to 620 miles on a single tank of fuel. While the cabin is not pressurized, allowing for a recommended altitude ceiling of 10,000 feet, the AirCar is equipped to go higher with supplementary oxygen tanks. This allows it to seamlessly integrate into existing air traffic while being suitable for everyday gas station refueling.

What licenses do you need to operate the AirCar?

To legally operate the AirCar on roads, owners will need a standard driver’s license, just like any conventional car. However, to fly, a private pilot’s license is required. The design of the aircraft allows individuals who already possess a private pilot’s license to fly the AirCar without the need for extensive retraining, making it accessible for a wider audience. This unique requirement means enthusiasts must be prepared to secure both driving and flying licenses, alongside access to an appropriate runway, to unleash the full capabilities of the AirCar.

Pricing and who the AirCar is for

Expected to retail between $800,000 and $1.2 million, the AirCar positions itself within the upper echelons of supercar pricing. This places it in the market for high-end consumers, including affluent business travelers and air taxi operators who are looking to evade urban congestion. While the financial barrier may be significant for many, the potential time savings and unique travel capabilities offered by this flying automobile make it an intriguing proposition for those willing to invest.

No.	Key Points
1	The AirCar is set to be certified for public use after years of development.
2	Transitioning from driving to flying takes about 80 seconds.
3	The vehicle’s performance includes speeds up to 155 mph and a range of 620 miles.
4	A standard driver’s license is required for road use, while a private pilot’s license is mandatory for flying.
5	The price of the AirCar positions it within a luxury market for affluent buyers.

Summary

The AirCar by Klein Vision represents a pivotal moment in transportation history, merging the realms of aviation and automotive engineering. As the project nears certification and prepares for the delivery of its first models, it promises to revolutionize travel and commute experiences, particularly for those living in congested urban environments. With an impressive range, rapid transition capabilities, and robust performance metrics, the AirCar could redefine how we navigate the roads and skies in the near future.

Frequently Asked Questions

Question: What type of engines power the AirCar?

The AirCar features three engine options, all 3.2-liter V6 engines sourced from Adept Airmotive, with varying horsepower outputs.

Question: How long does it take to switch from driving to flying?

The transformation from driving mode to flying mode takes approximately 80 seconds, allowing for a seamless transition.

Question: Who is the target market for the AirCar?

The AirCar is primarily targeted towards affluent buyers, including business travelers and air taxi operators who can afford the luxury price tag.

New AI Test Targets Patients for Promising Prostate Cancer Treatment

News Editor — Fri, 30 May 2025 11:23:53 +0000

This article is published by News Journos

A groundbreaking study presented at the American Society of Clinical Oncology’s annual meeting in Chicago reveals that an innovative artificial intelligence (AI) tool has the potential to improve health outcomes for men with prostate cancer. The AI technology identifies patients who are likely to benefit from the drug abiraterone, a treatment known to significantly reduce mortality among specific groups of prostate cancer patients. This advancement aims to optimize treatment strategies, ensuring that patients receive the most effective therapies while minimizing potential side effects.

Article Subheadings
1) AI’s Role in Identifying Cancer Treatment Efficacy
2) Understanding Abiraterone’s Mechanism and Benefits
3) Research Methodology and Key Findings
4) Implications for Healthcare Policies and Practices
5) A Call to Action: Access to Treatment

AI’s Role in Identifying Cancer Treatment Efficacy

The AI tool developed in this research is designed to analyze images of tumor samples to identify specific biomarkers. These biomarkers help in predicting which patients are likely to benefit from abiraterone. The development team, comprising researchers from leading UK institutions, highlighted the capability of AI to extract critical information from routine pathology slides that may not be visible to the naked eye. By implementing such technology, healthcare providers can ensure a more personalized treatment plan for prostate cancer patients, potentially leading to better outcomes.

Understanding Abiraterone’s Mechanism and Benefits

Abiraterone works by inhibiting the production of testosterone, a hormone that fuels the growth of prostate cancer cells. Research has shown that this drug can lower the risk of death by nearly 50% in one out of every four men diagnosed with prostate cancer. However, due to its high costs and potential side effects, medical authorities are cautious about its widespread prescription. The use of AI to identify suitable candidates for this treatment not only optimizes healthcare resources but also guards against the complications associated with unnecessary treatments.

Research Methodology and Key Findings

In a methodical approach, researchers utilized AI to analyze biopsy images from over 1,000 men who had previously participated in clinical trials. The findings revealed a stark difference in outcomes based on tumor biomarkers: for patients with biomarker-positive tumors, the mortality risk dropped from 17% to 9% following treatment with abiraterone. Conversely, those with biomarker-negative tumors did not experience significant improvements in mortality risk when treated with abiraterone, indicating that standard treatments such as hormone therapy and radiotherapy remain the appropriate course of action for these patients.

Implications for Healthcare Policies and Practices

The findings of this study underscore the need for a reevaluation of current healthcare guidelines surrounding the prescription of abiraterone. In the UK, while the drug has been approved for use in Scotland and Wales for high-risk, newly diagnosed prostate cancer, its availability in England is restricted to patients with metastasized cancer through the National Health Service. The research team advocates for a broader approach, suggesting that an estimated 8,400 men per year could benefit from access to this life-extending treatment if current restrictions are lifted.

A Call to Action: Access to Treatment

The researchers emphasized the disparities in access to abiraterone as a critical issue of public health. Reference was made to the “postcode lottery” in the UK, where access to life-saving drugs varies widely based on geographic location. Such inequalities affect patient outcomes and underscore the urgency for an overhaul in how treatments like abiraterone are prescribed. The study’s co-lead, Nick James, expressed concern that the current access framework is not equitable and called for actionable changes that allow all eligible patients to receive this essential drug.

No.	Key Points
1	AI can identify prostate cancer patients who would benefit from abiraterone treatment.
2	Abiraterone effectively lowers mortality risks for certain cancer patients, but has limitations and side effects.
3	The research methodology involved analyzing tumor samples from over 1,000 trial participants using AI.
4	The study advocates for reassessing current healthcare policies regarding the availability of abiraterone.
5	Access to treatment is inequitable, presenting a public health issue that needs addressing.

Summary

The introduction of AI tools in the realm of prostate cancer treatment represents a significant advance in personalized medicine. By identifying the subsets of patients most likely to benefit from treatments like abiraterone, healthcare providers can optimize their approach, minimizing the risks and costs associated with unnecessary therapies. This research not only has implications for individual treatment plans but also calls upon health authorities to rethink policies that restrict access to potentially life-saving medications.

Frequently Asked Questions

Question: What is abiraterone?

Abiraterone is a medication used to treat prostate cancer by blocking testosterone production, which can slow down the growth of cancer cells.

Question: How does artificial intelligence improve cancer treatment?

AI can analyze complex data such as tumor images to identify biomarkers, allowing healthcare professionals to target treatments more effectively based on individual patient profiles.

Question: Why is there a difference in access to abiraterone between different regions in the UK?

Access to abiraterone varies based on regional healthcare policies, resulting in what is referred to as a “postcode lottery,” where some patients can receive treatment while others cannot, depending on their location.

Trump Administration Cuts Funding for Moderna’s Bird Flu Vaccine Amid Promising Test Results

News Editor — Thu, 29 May 2025 11:20:53 +0000

This article is published by News Journos

The Health and Human Services Department has canceled a substantial $766 million funding agreement with drugmaker Moderna Inc., originally designated for developing a vaccine against potential pandemic influenza, notably including H5N1 bird flu. This decision, communicated to the company on Wednesday, has raised significant concerns about the implications for public health, given recent positive trial results for the vaccine. As Moderna explores alternative funding options, the incident marks a contentious chapter in the ongoing debate over mRNA vaccine technology and its role in pandemic preparedness.

Article Subheadings
1) Overview of the Funding Withdrawal
2) Moderna’s Vaccine Trial Results
3) Reactions from Health Experts
4) Broader Implications for Public Health
5) Future of mRNA Vaccine Development

Overview of the Funding Withdrawal

On Wednesday, the Health and Human Services Department officially notified Moderna Inc. that it was terminating a $766 million funding agreement aimed at supporting the development of a vaccine for emerging pandemic threats, particularly the H5N1 bird flu. The funding, awarded through the Biomedical Advanced Research and Development Authority (BARDA), was initially allocated in July 2024 and January 2025. This cancellation has occurred despite previous announcements praising the progress of mRNA technology in vaccine development, particularly in relation to the COVID-19 pandemic response.

The withdrawal of funds adds a layer of uncertainty to the project, which had been positioned as critical for future pandemic preparedness. Health Secretary Robert F. Kennedy Jr. has been vocal against mRNA vaccines, raising questions about the motivations behind the funding cut. Health officials argue that the investment in such technologies is imperative for public safety, especially in light of current pandemic threats.

Moderna’s Vaccine Trial Results

At the time of the funding cancellation, Moderna had been reporting positive interim results from early-stage trials of its vaccine, mRNA-1018, which was developed to target the H5 bird flu virus. This vaccine has utilized the same mRNA technology that was pivotal in the rapid development of COVID-19 vaccines, resulting in more than a billion doses administered globally. The trial involved 300 healthy adults, demonstrating a robust immune response alongside a favorable safety profile.

Despite the promising results, which could be vital in combatting a potential outbreak, the halting of funding raises concerns about the continuation of this vital research. In response to the funding cuts, Stephane Bancel, CEO of Moderna, expressed both concern and commitment, stating that the company is dedicated to exploring alternate avenues to fund the development and manufacturing processes for the vaccine. He emphasized the importance of continuing research in mRNA technology as a cornerstone in fighting emerging health threats.

Reactions from Health Experts

The reaction from the public health community has been one of alarm and disapproval. Dr. Ashish Jha, a public health expert and former COVID-19 response coordinator under President Biden, labeled the funding withdrawal as a grave risk to public health. He stated, “This move puts the lives of Americans at risk.” His remarks highlight the significance of consistent funding for vaccine research, particularly when there are indications that diseases like bird flu could mutate and become more virulent or transmissible among humans.

Critics argue that the suspension of funding not only jeopardizes the immediate project but could also deter future investments in mRNA technology, which has proven effective during the COVID-19 pandemic. The narrative surrounding mRNA vaccines remains contentious, with deeply polarized opinions, underscoring the challenge of reconciling scientific evidence with political viewpoints.

Broader Implications for Public Health

The cancellation of the funding contract may have far-reaching consequences for public health preparedness in the U.S. The H5N1 bird flu has already shown potential to spill over from wild birds to cattle and has sickened several individuals, although most cases have been mild. Nevertheless, significant concern remains regarding the virus’s ability to mutate, which could pose a serious threat leading to widespread infections. This mirrors the early warning signs that preceded the COVID-19 pandemic, where predictive measures were crucial in timely interventions.

Public health officials emphasize the necessity of ongoing investment in pharmaceutical research that can preemptively address such threats. The scenario raises important questions about the United States’ readiness to handle future pandemics, particularly when it relies on evolving technologies and innovation to circumvent biological threats. The decision to withdraw significant funding could be viewed as a setback in the collective ability to safeguard public health.

Future of mRNA Vaccine Development

As Moderna seeks alternative funding avenues, the discourse around mRNA research is evolving. Dr. Céline Gounder, an expert in public health, has remarked on the ongoing exploration of mRNA’s potential, stating that it took over 30 years of research to realize its capabilities in combatting pandemics. Indeed, the rapid deployment of mRNA-based COVID-19 vaccines has set a new precedent in pandemic response, but the current situation could hamper progress in similar future applications.

Despite the funding setbacks, innovation in vaccine development is poised to continue. The discussions surrounding the effectiveness of mRNA versus traditional vaccine approaches will essentially shape public health policy moving forward. As the repository of knowledge expands, experts contend that with the right focus and funding, mRNA technology could evolve to address a variety of health challenges beyond influenza, allowing for a more agile response to future pandemics.

No.	Key Points
1	The Health and Human Services Department has canceled a $766 million funding agreement with Moderna for developing a bird flu vaccine.
2	Moderna’s early-stage vaccine trials reported positive results, demonstrating a robust immune response.
3	Experts warn that the funding withdrawal poses significant risks to public health and pandemic preparedness.
4	Concerns abound regarding the mutation of H5N1 and its potential to cause widespread infection.
5	The future of mRNA vaccine technology remains uncertain, hinging on renewed funding and support.

Summary

The cancellation of critical funding for Moderna’s H5N1 vaccine demonstrates the fragility of public health initiatives at a time when pandemic preparedness is paramount. As health experts voice grave concerns about the implications of this decision, the broader discourse surrounding mRNA technology intensifies. The need for continued investment in groundbreaking scientific research cannot be overstated if society aims to fend off emerging health threats effectively.

Frequently Asked Questions

Question: What is the significance of the canceled funding for Moderna?

The cancellation poses significant risks to the development of the H5N1 bird flu vaccine and underscores the challenges in funding essential public health initiatives.

Question: How effective has the mRNA approach been in past vaccinations?

The mRNA approach has been remarkably effective during the COVID-19 pandemic, allowing for rapid vaccine rollout and demonstrating substantial safety and efficacy.

Question: What are the implications of bird flu mutations?

There is concern that mutations of the H5N1 virus could enable it to spread more easily among humans, potentially leading to a pandemic scenario.

BYD Unveils New Technology Promising Five-Minute EV Charging, Boosting Shares

News Editor — Tue, 18 Mar 2025 04:26:27 +0000

This article is published by News Journos

Shares of BYD, a leading Chinese electric vehicle manufacturer, saw a significant rise following the announcement of its revolutionary “Super e-Platform” technology. This new development promises to transform the electric vehicle charging landscape, allowing EVs to gain substantial range with much shorter charging times. This technological leap not only positions BYD favorably against international rivals but also aims to alleviate common consumer concerns surrounding electric vehicle range.

Article Subheadings
1) BYD’s New Charging Technology Announcement
2) Comparisons to Competitors
3) Addressing Range Anxiety
4) Implications for Electric Vehicle Owners
5) Future Investments and Developments

BYD’s New Charging Technology Announcement

On March 11, 2025, Wang Chuanfu, Chairman and President of BYD, introduced their latest technological innovation, the “Super e-Platform,” during a launch event. This platform promises to revolutionize electric vehicle charging by enabling peak charging speeds of up to 1,000 kilowatts. Such advancements would allow vehicles equipped with this platform to achieve a range of approximately 400 kilometers (around 249 miles) with just a five-minute charge. This claim significantly contrasts the current capabilities of many EVs in the market, indicating a potential breakthrough in the industry’s approach to charging infrastructure.

Following the announcement, BYD’s shares surged by more than 6% in Hong Kong, marking a new 52-week high. The company’s Shenzhen-listed stock also followed suit, indicating robust market confidence in BYD’s future. With stock prices climbing significantly in recent months—up more than 51% year-to-date—BYD appears to be a frontrunner in the electric vehicle sector, garnering attention from investors and analysts alike.

Comparisons to Competitors

In the realm of electric vehicle charging, competition remains fierce. Comparatively, Tesla’s latest superchargers can deliver charges at a rate of up to 500 kilowatts, permitting drivers to add approximately 270 kilometers of range in a mere 15 minutes. Additionally, other industry giants, such as Germany’s Mercedes-Benz, recently announced their new all-electric model capable of adding up to 325 kilometers of range within 10 minutes utilizing advanced charging technology. BYD’s announcements not only elevate its status but also set a benchmark that competitors must strive to surpass.

The impressive capabilities of BYD’s new charging technology call into question the existing methods and technologies employed by other manufacturers. Various analysts, including independent expert Xing Lei, have lauded BYD’s innovations as groundbreaking, which could press other brands to expedite their technological advancements to remain competitive. The market’s response to these innovations will be indicative of consumers’ preferences and the broader industry’s focus on electrification.

Addressing Range Anxiety

Range anxiety remains a significant hurdle preventing more consumers from adopting electric vehicles. This concern centers on the fear of running out of charge before reaching a destination. BYD addresses this challenge head-on with its new fast-charging technology. By promising a charging time comparable to refueling a gasoline car, BYD aims to alleviate consumers’ fears and encourage a wider transition to electric vehicles.

As Wang Chuanfu noted during the announcement, “The ultimate solution is to make charging as quick as refueling a gasoline car.” BYD’s strategies are geared toward consolidating its position in the EV market and boosting consumer confidence. By constantly improving charging technologies, manufacturers like BYD can help shift the narrative and perceptions surrounding electric vehicle viability.

Implications for Electric Vehicle Owners

Experts suggest that the introduction of more efficient charging platforms may lead to a behavioral change among EV owners. Currently, most EV owners charge their vehicles by topping off the battery sporadically rather than completely depleting it and then charging from zero to full. Michael Dunne, a notable figure in the automotive analysis field, indicated that the capability to charge an EV within mere minutes could encourage these owners to adopt even more dynamic charging habits.

Furthermore, BYD’s plans to install over 4,000 ultra-fast charging units throughout China complement its technological advancements. While specific details regarding the timeline and investment for these chargers remain undisclosed, the anticipation surrounding the launch is palpable. Electric vehicle owners are likely to benefit significantly from the expanded infrastructure, which should reduce concerns over accessibility to charging stations.

Future Investments and Developments

In addition to unveiling its new technology, BYD has also made strategic financial moves aimed at bolstering its growth and innovation. Earlier in March, the company initiated a sale of its Hong Kong shares, seeking to raise approximately $5.2 billion to enhance its research and development. The endeavors are reflective of BYD’s commitment to maintaining its trajectory in a rapidly evolving industry.

As the electric vehicle market evolves, BYD’s emphasis on both innovation and infrastructure development will likely play a critical role in shaping its future. The company’s willingness to invest in new technologies and takeaway learnings from its competitions may secure its position as a leading player in the electric mobility sector.

No.	Key Points
1	BYD launched a new “Super e-Platform” capable of charging vehicles in just 5 minutes for 400 km range.
2	BYD’s share prices rose significantly after the announcement, signaling positive investor sentiment.
3	The charging technology is expected to alleviate consumer concerns surrounding range anxiety.
4	BYD plans to install over 4,000 ultra-fast charging units across China to support its new technology.
5	Investments are being made to bolster research and development efforts within the electric vehicle sector.

Summary

The launch of BYD’s “Super e-Platform” technology marks a significant milestone in electric vehicles, potentially changing the game for charging times and range capabilities. As the company continues to invest in its infrastructure and technology, it is poised to set new standards in the market, appealing to a broader audience of consumers wary of switching to electric vehicles. This advancement not only highlights BYD’s commitment to innovation but serves as a warning to its competitors to keep pace with the evolving expectations of consumers.

Frequently Asked Questions

Question: What is BYD’s “Super e-Platform” technology?

BYD’s “Super e-Platform” is a new technology that enables electric vehicles to charge at peak speeds of up to 1,000 kilowatts, potentially allowing for a 400 kilometers range with only five minutes of charging time.

Question: How does BYD’s new charging technology compare to Tesla?

Tesla’s latest charging stations offer up to 500 kilowatts of charging power, adding around 270 kilometers of range in 15 minutes. BYD’s new technology seeks to surpass these capabilities significantly.

Question: What are the implications of faster charging times for electric vehicle owners?

Faster charging times may encourage EV owners to change their charging habits, allowing for more frequent topping up rather than waiting for a full charge, thereby contributing to greater accessibility and convenience of electric vehicles.